Repertoire Immune Medicines is a biotechnology company that is developing a new class of immune medicines. The company's proprietary DECODE discovery platform enables the rapid identification of novel immune targets and the development of highly specific and effective immune medicines. Repertoire's lead product candidate, RPTR-146, is a potential treatment for solid tumors and is currently in Phase 1 clinical trials. The company was founded in 2017 and is headquartered in Cambridge, MA.